Timo Gaiser

Mannheim, BW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 122 publications

Corrigendum to "Loss of c-Met signaling sensitizes hepatocytes to lipotoxicity and induces cholestatic liver damage by aggravating oxidative stress" [Toxicology 361-362 (2016) 39-48].

Corrigendum to "Loss of c-Met signaling sensitizes hepatocytes to lipotoxicity and induces cholestatic liver damage by aggravating oxidative stress" [Toxicology 361-362 (2016) 39-48].

Journal: Toxicology

Published: November 26, 2025

A pipeline of machine learning-driven multi-modal data fusion methods for prognostic risk analysis in bevacizumab-treated metastatic colorectal cancer.

A pipeline of machine learning-driven multi-modal data fusion methods for prognostic risk analysis in bevacizumab-treated metastatic colorectal cancer.

Journal: Scientific reports

Published: August 14, 2025

Corrigendum to "mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214) and the ABCSG (R-06)": [ESMO Open 9 (2024) 103703].

Corrigendum to "mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214) and the ABCSG (R-06)": [ESMO Open 9 (2024) 103703].

Journal: ESMO open

Published: February 22, 2025

Predicting benefit from PARP inhibitors using deep learning on H&E-stained ovarian cancer slides.

Predicting benefit from PARP inhibitors using deep learning on H&E-stained ovarian cancer slides.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 03, 2024

mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214).

mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214).

Journal: ESMO open

Published: June 19, 2024

Clinical impact of panel gene sequencing on therapy of advanced cancers of the digestive system: a retrospective, single center study.

Clinical impact of panel gene sequencing on therapy of advanced cancers of the digestive system: a retrospective, single center study.

Journal: BMC cancer

Published: November 27, 2023

Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial.

Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: November 14, 2023

PARP-1 selectively impairs KRAS-driven phenotypic and molecular features in intrahepatic cholangiocarcinoma.

PARP-1 selectively impairs KRAS-driven phenotypic and molecular features in intrahepatic cholangiocarcinoma.

Journal: Gut

Published: October 19, 2023

Analysis of cell free DNA to predict outcome to bevacizumab therapy in colorectal cancer patients.

Analysis of cell free DNA to predict outcome to bevacizumab therapy in colorectal cancer patients.

Journal: NPJ genomic medicine

Published: September 22, 2023

Deep learning to predict breast cancer sentinel lymph node status on INSEMA histological images.

Deep learning to predict breast cancer sentinel lymph node status on INSEMA histological images.

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 11, 2023

Colorectal cancer risk stratification on histological slides based on survival curves predicted by deep learning.

Colorectal cancer risk stratification on histological slides based on survival curves predicted by deep learning.

Journal: NPJ precision oncology

Published: April 11, 2023

Cyclin A2 Expression as Predictive Biomarker in Muscle-Invasive Upper Tract Urothelial Carcinoma.

Cyclin A2 Expression as Predictive Biomarker in Muscle-Invasive Upper Tract Urothelial Carcinoma.

Journal: Urologia internationalis

Published: March 25, 2023

Showing 1-12 of 122

Last Updated: 09/26/2026